Skip to content
cccskills
FreePublished on GitHub

es-cushing-postop-pituitary-mri-within-1-3-months

This skill recommends obtaining a postoperative pituitary MRI within 1–3 months after successful transsphenoidal surgery (TSS) to establish a new baseline for future recurrence assessment. Use when a Cushing’s syndrome patient has achieved biochemical remission post‑TSS and is entering routine follow‑up.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.5 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Obtaining Postoperative Pituitary MRI Scan Within 1-3 Months After Successful TSS

STEP 1 — Gather Information

Collect postoperative day 5–7 urine free cortisol (UFC) or late-night salivary cortisol, morning serum cortisol, clinical assessment of remission (no symptoms of hypercortisolism), and date of successful transsphenoidal surgery (TSS). Confirm biochemical remission (e.g., UFC < upper limit of normal or morning cortisol <5 µg/dL) and stable clinical status.

STEP 2 — Rule In / Rule Out

Is the patient in biochemical remission after TSS? If yes, proceed to timing assessment; if no, evaluate for persistent disease and consider additional treatment per guideline 4.2.

STEP 3 — Classify or Stratify

Determine time since TSS: <1 month (early postoperative), 1–3 months (optimal window), or >3 months (delayed). If within 1–3 months, schedule MRI now; if <1 month, defer until 1 month; if >3 months, obtain MRI as soon as feasible and note delayed baseline.

STEP 4 — Decide

Obtain a dedicated pituitary MRI protocol with contrast (unless contraindicated) to establish a new postoperative baseline; document findings for future recurrence comparison.

Clinical Guardrails / Mimics / Pitfalls

Do not obtain MRI before 1 month postoperative to avoid mistaking postoperative blood or edema for residual tumor; do not rely solely on MRI for recurrence—combine with biochemical testing; avoid delaying beyond 3 months without justification as baseline may miss early recurrence; ensure MRI uses thin-cut sagittal and coronal views with dynamic contrast if possible; avoid non‑contrast studies unless contraindicated.

Concrete Clinical Example

A 48‑year‑old woman with Cushing’s disease underwent uncomplicated TSS. Post‑op day 6 UFC was normal and morning cortisol 3 µg/dL, confirming remission. At 8 weeks post‑TSS, a contrast‑enhanced pituitary MRI showed no residual adenoma; this scan was stored as the new baseline for annual follow‑up.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill